FDA Grants Fast-Track Designation to CMD-003 for Lymphomas and PTLD

The U.S. Food and Drug Administration (FDA) granted fast-track designation to CMD-003 for the treatment of diseases associated with the Epstein Barr virus, such as relapsed/refractory lymphoma and post-transplant lymphoproliferative diseases (PTLD).

CMD-003 is an investigational therapy that consists of patients’ T cells that are activated to attack malignant cells expressing Epstein Barr virus antigens. The agent is being evaluated in two clinical trials of patients with extranodal natural killer T-cell lymphoma and Epstein Barr virus-associated diffuse large B-cell lymphoma, Hodgkin lymphoma, and PTLD.

Source: Cell Medica press release, February 21, 2017.